EPO and myelodysplastic syndrome: These data also provide a biological rationale for the results of a recent Groupe Francais des Myelodysplasies (GFM) study group phase II trial that compared treatment with lenalidomide to combined treatment with lenalidomide and epoetin beta in lower risk, transfusion dependent MDS patients who had failed prior treatment with recombinant erythropoietins [18].